Abstract
Heart failure (HF) affects 1 in 4 Americans and significantly contributes to rising health care costs. Biomarkers are pivotal in the management of HF; however, they must be interpreted in the context of individual clinical characteristics for accurate interpretation. This review outlines the integration of natriuretic peptides and cardiac troponins into clinical practice using current HF guidelines. Evidence on the role of soluble suppression of tumorigenesis-2 and galectin-3 as HF biomarkers is briefly reviewed. Nurse practitioners are well-situated to use biomarkers in clinical decision-making to improve patient outcomes. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.